Your browser is no longer supported. Please, upgrade your browser.
Settings
MNOV MediciNova Inc. daily Stock Chart
MNOV [NASD]
MediciNova Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own0.40% Shs Outstand32.73M Perf Week-5.25%
Market Cap218.64M Forward P/E41.75 EPS next Y0.16 Insider Trans0.00% Shs Float26.78M Perf Month-25.11%
Income-10.00M PEG- EPS next Q-0.07 Inst Own21.00% Short Float8.40% Perf Quarter51.82%
Sales- P/S- EPS this Y12.90% Inst Trans-4.01% Short Ratio7.39 Perf Half Y125.68%
Book/sh1.29 P/B5.18 EPS next Y151.60% ROA-27.40% Target Price11.00 Perf Year67.00%
Cash/sh0.84 P/C7.92 EPS next 5Y20.00% ROE-31.70% 52W Range2.62 - 10.16 Perf YTD88.17%
Dividend- P/FCF- EPS past 5Y27.20% ROI- 52W High-34.25% Beta0.96
Dividend %- Quick Ratio27.30 Sales past 5Y- Gross Margin- 52W Low154.96% ATR0.56
Employees10 Current Ratio27.30 Sales Q/Q- Oper. Margin- RSI (14)37.57 Volatility4.02% 5.50%
OptionableNo Debt/Eq0.00 EPS Q/Q-23.40% Profit Margin- Rel Volume0.37 Prev Close6.84
ShortableYes LT Debt/Eq0.00 EarningsApr 28 Payout- Avg Volume304.54K Price6.68
Recom1.50 SMA20-17.14% SMA50-4.84% SMA20054.45% Volume111,829 Change-2.34%
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
May-03-16 01:04PM  MEDICINOVA INC Financials EDGAR Online Financials
Apr-29-16 04:25PM  MNOV: Positive Trends Seen in Preliminary Data Presented on MN-166 in ALS Zacks Small Cap Research
Apr-28-16 06:21AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Apr-27-16 04:55PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Apr-20-16 06:00AM  MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada GlobeNewswire -6.56%
Apr-04-16 08:02AM  MediciNova, Inc. (NASDAQ: MNOV) - Analyst Coverage Initiated; Report by Broad Street Accesswire +13.92%
Mar-31-16 07:55AM  MediciNova Gains 6% Following Positive Mention In Medical Journal
06:32AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Offic
Mar-30-16 07:00PM  MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence GlobeNewswire +11.11%
Mar-27-16 07:20PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China at noodls
07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China GlobeNewswire
Mar-23-16 07:27PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia at noodls
07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia GlobeNewswire
Mar-22-16 06:29AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis at noodls
06:09AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for Progressive Multiple Sclerosis GlobeNewswire
Mar-14-16 01:57PM  LifeSci Capital Initiates Coverage of MediciNova Accesswire
09:00AM  Biotech Trade Report Accesswire
Mar-09-16 11:00AM  MNOV: Multiple Catalysts Ahead in 2016
Mar-07-16 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) GlobeNewswire
Mar-06-16 06:00PM  MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas GlobeNewswire
Mar-01-16 08:46AM  MediciNova, Inc. (NASDAQ: MNOV) Ongoing Clinical Trial of MN-166 Accesswire
Feb-26-16 09:15AM  3 Stocks That Should be in Your Portfolio Today Accesswire -10.59%
06:41AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Feb-25-16 05:19PM  MEDICINOVA INC Files SEC form 10-K, Annual Report +10.69%
03:04PM  3 Biotech Stocks to Consider Buying Right Now Accesswire
10:15AM  4 Stocks That Are Starting To Attract Major Attention Today Accesswire
Feb-22-16 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada GlobeNewswire +5.98%
Feb-11-16 06:00PM  MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas GlobeNewswire
Feb-07-16 06:00PM  MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas GlobeNewswire
Jan-27-16 06:18PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis at noodls
06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis GlobeNewswire
Jan-18-16 06:00PM  FDA Grants Rare Pediatric Disease Designation to MediciNovas MN-166 (ibudilast) for the Treatment of Krabbe Disease GlobeNewswire
Jan-13-16 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe GlobeNewswire
Dec-16-15 02:30PM  MNOV: Positive Interim Safety and Clinical Data Presented at 26th International Symposium on ALS/MND
06:00AM  FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis GlobeNewswire
Dec-14-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in China GlobeNewswire
Dec-13-15 06:00PM  MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL GlobeNewswire
Dec-09-15 05:30PM  MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting GlobeNewswire
Dec-06-15 06:00PM  MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, California GlobeNewswire
Dec-02-15 07:45AM  Evaluating the Technicals - Research on Hudson Technologies, Retractable Technologies, Spark Networks and MediciNova Accesswire
Nov-27-15 08:06AM  Is MediciNova, Inc. (MNOV) A Good Stock To Buy? at Insider Monkey
Nov-23-15 09:56AM  Is Timmins Gold Corp (TGD) A Good Stock To Buy? at Insider Monkey
Nov-19-15 06:00AM  MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia GlobeNewswire
Nov-10-15 06:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan GlobeNewswire
Nov-09-15 06:00PM  FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of ALS; MediciNova Plans to Initiate a Clinical Trial with MGH (Massachusetts General Hospital) GlobeNewswire
Nov-04-15 06:00AM  MediciNova Announces Interim Data From Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at the 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting in Clearwater Beach, Florida GlobeNewswire
Nov-02-15 03:00PM  MNOV: Presentation on ALS Phase 2 Study in December
Oct-30-15 06:14AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Oct-29-15 05:19PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Oct-13-15 07:00PM  MediciNova to Present Preclinical Data on MN-166 (ibudilast) at the 26th International Symposium on ALS/MND in Orlando, FL GlobeNewswire
Oct-09-15 06:00AM  MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF GlobeNewswire
Sep-25-15 05:11PM  15 Stocks Moving In Friday's After-Hours Trading
05:02PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-24-15 06:00AM  MediciNova to Present at the Ladenburg Thalmann 2015 Healthcare Conference GlobeNewswire
Sep-10-15 06:00AM  FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-08-15 11:35AM  MNOV: Phase 2 ALS Trial Expanded
Sep-02-15 07:00PM  MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast) GlobeNewswire
Sep-01-15 06:06AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Aug-25-15 06:04AM  MEDICINOVA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-24-15 07:00PM  MediciNova Announces Closing of Underwritten Public Offering of Common Stock GlobeNewswire
Aug-19-15 06:07AM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Aug-18-15 07:43PM  MediciNova Announces Pricing of Underwritten Public Offering of Common Stock GlobeNewswire
05:01PM  Tuesday's After-Hours Movers Led By Analog Devices, Canadian Solar And Weibo
04:00PM  MediciNova Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
Aug-03-15 01:45PM  MNOV: Ready to Initiate Phase 2 Trials of MN-001 in IPF and NASH
Aug-01-15 08:09PM  10-Q for MediciNova, Inc. at Company Spotlight
Jul-31-15 06:20AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Jul-30-15 06:07PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Jul-28-15 06:00AM  MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 26th International Symposium on ALS/MND in Orlando, FL: Interim Safety and Clinical Outcomes to be Presented GlobeNewswire
Jul-27-15 02:11PM  MediciNova, Inc. (MNOV)s Stock Jumps on FDA Approval of Second Protocol at Insider Monkey +8.55%
12:36PM  Market Update: Monday's Mid-Day Movers, China's Stock Market Crash And More
08:00AM  MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia GlobeNewswire
Jul-21-15 08:00AM  MediciNova Announces Update on Development Plans for MN-001 in IPF GlobeNewswire
Jul-02-15 04:08PM  MEDICINOVA INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Jun-30-15 07:00PM  MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence GlobeNewswire
Jun-24-15 09:00AM  MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting GlobeNewswire
Jun-16-15 06:00AM  MediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology GlobeNewswire
Jun-15-15 06:25AM  MEDICINOVA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-12-15 06:00AM  MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
Jun-03-15 08:00AM  MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease GlobeNewswire
May-22-15 05:14PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive A
May-13-15 08:11PM  10-Q for MediciNova, Inc. at Company Spotlight
May-12-15 06:16AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
May-11-15 05:46PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
May-07-15 09:07AM  MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at noodls
08:00AM  MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
May-06-15 10:20AM  MNOV: MediciNova's Deep Pipeline Is Meaningfully Undervalued
May-05-15 08:12PM  10-K for MediciNova, Inc. at Company Spotlight
Apr-29-15 06:15AM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers
Apr-23-15 07:21PM  Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting at noodls
07:00PM  Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting GlobeNewswire
Apr-21-15 02:03PM  MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS at noodls
01:45PM  MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Apr-16-15 02:21PM  MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation at TheStreet +41.31%
08:41AM  Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan at noodls
08:30AM  Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan GlobeNewswire
08:12AM  FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis at noodls
08:00AM  FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis GlobeNewswire
Apr-03-15 02:31PM  MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Mar-14-15 01:55AM  MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting of the College on Problems of Drug Dependence in Phoenix, Arizona at noodls
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. Its product candidates include MN-166 (ibudilast), an anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence; MN-221 (bedoradrine), a 2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a novel tubulin binding agent for the treatment of solid tumor cancers. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.